Allergy chest congestion medication can make a significant difference to daily life when allergic reactions cause nasal blockage, post-nasal drip, or lower-airway symptoms such as chest tightness and wheeze. Allergies trigger the release of histamine and other inflammatory mediators, which can affect both the upper and lower airways. Understanding which medicines are appropriate — from antihistamines and intranasal corticosteroids to decongestants and inhaled therapies — is essential for safe, effective management. This article explains how allergies cause chest congestion, outlines the main treatment options available in the UK, and provides NHS- and NICE-aligned guidance on choosing and using these medications safely.

How Allergies Cause Chest Congestion

Allergic reactions occur when the immune system identifies a harmless substance — such as pollen, dust mites, pet dander, or mould — as a threat. In response, immune cells release chemical mediators, most notably histamine, which trigger inflammation primarily in the upper airways. In some individuals, this inflammatory process extends into the lower airways, contributing to chest symptoms.

When allergens are inhaled, the nasal and bronchial lining can become swollen and irritated, leading to increased mucus production. In the upper airways, this produces nasal blockage and post-nasal drip, which can irritate the throat and cause a sensation of chest heaviness or a persistent cough. In the lower airways, smooth muscle contraction and airway narrowing produce chest tightness and wheeze — symptoms that suggest lower-airway involvement and possible allergic asthma. In people with allergic asthma, the airways become hyperresponsive, making symptoms significantly worse upon allergen exposure.

It is important to distinguish between upper-airway symptoms (nasal blockage, post-nasal drip, throat irritation) and lower-airway symptoms (chest tightness, wheeze, breathlessness), as they may require different treatments. Allergy-related symptoms typically:

• Occur seasonally or upon exposure to a known trigger

• Are accompanied by sneezing, itchy eyes, or a runny nose

• Do not usually cause fever

Note that green or yellow mucus and fever can occur in viral illnesses as well as bacterial infections and are not on their own reliable indicators of the cause; clinical assessment is needed if you are uncertain.

If chest symptoms are severe, persistent, or accompanied by breathlessness, wheeze, or fever, it is essential to seek medical advice promptly, as these may indicate asthma, a chest infection, or another underlying condition requiring different management. Repeated or severe lower-airway symptoms alongside allergies warrant formal assessment for asthma.

Medications Used to Treat Allergy-Related Chest Congestion

Several classes of medication are used to manage allergy-related symptoms, each targeting different aspects of the allergic and inflammatory response. The choice of treatment depends on the severity and location of symptoms, the presence of co-existing conditions such as asthma, and individual patient factors.

Antihistamines are often used as first-line treatment for mild to moderate allergic symptoms such as sneezing, itching, and runny nose (rhinorrhoea). They work by blocking H1 histamine receptors. It is important to note that oral antihistamines have limited effect on nasal blockage; intranasal corticosteroids or short-term decongestants are more effective for this symptom. Second-generation antihistamines such as cetirizine and loratadine are preferred due to their reduced sedating profile and are widely available over the counter in the UK. Fexofenadine 120 mg is available as a pharmacy (P) medicine; higher-strength formulations (e.g., 180 mg) are generally prescription-only — check with your pharmacist.

Intranasal corticosteroids (e.g., beclometasone nasal spray, fluticasone nasal spray) are highly effective for reducing upper airway inflammation, nasal blockage, and post-nasal drip, and are recommended by NICE CKS as first-line treatment for moderate-to-severe or persistent allergic rhinitis. By reducing nasal inflammation and post-nasal drip, they can indirectly relieve throat irritation and associated chest discomfort. For lower-airway involvement, inhaled corticosteroids (e.g., beclometasone inhaler) are the cornerstone of allergic asthma management per NICE NG80.

Decongestants such as pseudoephedrine (oral) or xylometazoline (nasal spray) act by constricting blood vessels in the nasal mucosa, providing short-term relief of nasal congestion and blockage. They do not treat lower-airway symptoms such as chest tightness, wheeze, or asthma. They should be used only for short courses and are not suitable for everyone (see the safety section below). The MHRA issued updated safety advice on pseudoephedrine in 2024 regarding rare but serious risks (PRES/RCVS); always read the product information before use.

Leukotriene receptor antagonists such as montelukast may be considered as an add-on treatment in patients with both allergic rhinitis and asthma where other therapies have not provided adequate control, or where rhinitis coexists with asthma. Montelukast is not a first-line treatment for allergic rhinitis alone. Importantly, the MHRA issued a Drug Safety Update in 2019 highlighting the risk of neuropsychiatric reactions with montelukast (including sleep disturbances, mood changes, and suicidal thoughts). Patients and carers should seek medical advice promptly if any changes in mood, behaviour, or sleep occur.

Non-pharmacological measures — such as saline nasal irrigation and allergen avoidance — can complement medication and are recommended by NICE CKS. Intranasal antihistamines (e.g., azelastine) offer an alternative for rhinitis symptoms. For patients with refractory allergic rhinitis, allergen immunotherapy may be considered under specialist care.

If you are unsure which treatment is appropriate for you, speak to a pharmacist or GP.

Choosing the Right Treatment: NHS and NICE Guidance

NICE and the NHS provide clear frameworks for managing allergic conditions, including those presenting with chest symptoms. A structured, stepwise approach is recommended, beginning with the least invasive and lowest-risk treatments before escalating to prescription therapies.

For mild intermittent symptoms, NICE CKS (Allergic rhinitis) recommends starting with an oral second-generation antihistamine or an intranasal corticosteroid, both of which are available without prescription. Patients should be advised to identify and, where possible, avoid their allergen triggers. The NHS advises that if symptoms are not adequately controlled with over-the-counter treatment, a GP review is warranted.

When chest tightness, wheeze, or breathlessness are present alongside allergy symptoms, NICE NG80 (Asthma: diagnosis, monitoring and chronic asthma management) recommends formal assessment to confirm or exclude asthma. This should include spirometry and, where available, fractional exhaled nitric oxide (FeNO) measurement, in addition to a structured clinical history. Peak flow monitoring may support ongoing assessment. Spirometry is generally appropriate from around age 5 years; clinical judgement guides assessment in younger children.

If asthma is confirmed, a short-acting beta-2 agonist (SABA) such as salbutamol is prescribed for acute relief, with an inhaled corticosteroid added for persistent symptoms in line with NICE NG80 treatment steps. NICE QS25 (Asthma quality standard) sets out standards for ongoing monitoring and review.

Seek a GP or primary care review if any of the following apply:

• Symptoms are not responding to standard over-the-counter treatments

• Chest symptoms occur at rest or are disrupting sleep

• You are using a reliever inhaler (SABA) three or more times per week, experiencing night waking due to symptoms, or finding that symptoms are limiting your daily activities — these suggest poor asthma control

• You have any history of severe allergic reaction

Consider specialist referral if there is diagnostic uncertainty, symptoms are severe or difficult to control, there are frequent exacerbations, high-dose therapy is being considered, or allergen immunotherapy is being explored.

The MHRA and EMA periodically review the safety profiles of allergy medications. Patients should always check current product information or consult a pharmacist before starting a new medicine, and report any suspected side effects via the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk).

How to Use These Medications Safely

Using allergy medication safely requires an understanding of correct dosing, potential side effects, and important drug interactions. Even medications available over the counter carry risks if used incorrectly or in unsuitable patient groups.

Antihistamines are generally well tolerated. First-generation options (e.g., chlorphenamine) can cause significant drowsiness and should not be taken before driving or operating machinery. They are generally not recommended in elderly patients due to the risk of confusion and urinary retention. Second-generation antihistamines (e.g., cetirizine, loratadine) are safer for most adults, but may still cause drowsiness in some individuals — caution with driving or operating machinery is advised until you know how the medicine affects you. Dose adjustment may be required in patients with renal impairment; check the product information or ask your pharmacist.

Intranasal and inhaled corticosteroids are considered safe for long-term use at recommended doses. Patients should be counselled on correct technique to maximise efficacy and minimise side effects such as nasal irritation or oral thrush (with inhaled preparations). Using a spacer device with metered-dose inhalers and rinsing the mouth after use significantly reduces the risk of local side effects. At higher doses or with prolonged use, inhaled corticosteroids may have systemic effects (such as adrenal suppression or, in children, effects on growth); always use the lowest effective dose and discuss any concerns with your GP.

Decongestants should be used only for short periods. Topical nasal decongestants (e.g., xylometazoline nasal spray) should not be used for more than five to seven consecutive days to avoid rebound nasal congestion (rhinitis medicamentosa). Oral decongestants (e.g., pseudoephedrine) should also be taken for short courses only; if you feel you need them regularly, seek GP advice. Decongestants are not suitable for treating chest tightness, wheeze, or asthma.

Decongestants are not recommended for children under 6 years of age. For children aged 6–12, seek pharmacist or GP advice before use.

Patients with the following conditions should seek pharmacist or GP advice before using decongestants, as they may not be suitable:

• High blood pressure or cardiovascular disease

• Hyperthyroidism

• Glaucoma

• Diabetes

Decongestants are contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). The MHRA issued updated safety advice in 2024 on the risk of rare but serious neurological events (PRES/RCVS) with pseudoephedrine; always read the current product information.

Montelukast: The MHRA issued a Drug Safety Update in 2019 warning of neuropsychiatric reactions associated with montelukast, including nightmares, sleep disturbances, anxiety, depression, and suicidal thoughts. Patients and carers should be made aware of these risks before starting treatment and should seek medical advice promptly if any changes in mood, behaviour, or sleep are noticed.

Patients should always inform their GP or pharmacist of all medications they are taking, including herbal remedies, to avoid interactions. Pregnant or breastfeeding women should seek professional advice before using any allergy medication.

If symptoms worsen suddenly, or if there is any difficulty breathing, chest pain, or swelling of the face or throat, call 999 or go to your nearest A&E immediately, as these may indicate a serious allergic reaction or severe asthma attack.

Suspected side effects from any medicine can be reported to the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk — this helps improve medicine safety for everyone.

Frequently Asked Questions